Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
Status:
Completed
Trial end date:
2020-03-28
Target enrollment:
Participant gender:
Summary
The investigators hypothesise that empagliflozin 10mg daily will have haemodynamic, cardiac,
and renal benefits compared to placebo over 36 weeks in heart failure patients with type 2
diabetes (or pre-diabetes), leading to measurable improvements in clinical measures of
cardiac structure and function (LVESVI, and LV strain) as well as renal blood flow.